Litigation Details for HORIZON THERAPEUTICS, LLC v. PAR PHARMACEUTICAL, INC. (D.N.J. 2016)
✉ Email this page to a colleague
HORIZON THERAPEUTICS, LLC v. PAR PHARMACEUTICAL, INC. (D.N.J. 2016)
| Docket | ⤷ Sign Up | Date Filed | 2016-06-30 |
| Court | District Court, D. New Jersey | Date Terminated | 2018-10-03 |
| Cause | 15:1126 Patent Infringement | Assigned To | Robert B. Kugler |
| Jury Demand | None | Referred To | Joel Schneider |
| Parties | HORIZON THERAPEUTICS, LLC | ||
| Patents | 9,095,559; 9,254,278; 9,326,966 | ||
| Attorneys | JASON B. LATTIMORE | ||
| Firms | McCarter and English, LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in HORIZON THERAPEUTICS, LLC v. PAR PHARMACEUTICAL, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for HORIZON THERAPEUTICS, LLC v. PAR PHARMACEUTICAL, INC. (D.N.J. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2016-06-30 | 1 | United States Patent Nos. 9,095,559 (“the ’559 patent”), 9,254,278 (“the ’278 patent”), and 9,326,966…FOR INFRINGEMENT OF U.S. PATENT NO. 9,095,559 28. Plaintiff re-alleges and incorporates by…has infringed one or more claims of U.S. Patent No. 9,095,559; B. A judgment declaring that…attendant FDA regulations, the ’559 patent, the ’278 patent, and the ’966 patent are listed in the FDA publication…NDA. 20. The ’559 patent, the ’278 patent, and the ’966 patent qualify for listing in the | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
